Business context and reporting period
This is Pieris Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2015 (and nine months ended that date). The request metadata names “Pavella Therapeutics, Inc.,” which does not match the registrant identified in the filing. Pieris is a clinical-stage biotechnology company developing Anticalin-based medicines; it had no product-sales revenue and relied on collaborations, grants and equity financing.
Financial performance and position
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $415,000 | $19,000 | $792,000 | $2.090 million |
| Research and development expense | $2.052 million | $927,000 | $5.302 million | $3.268 million |
| General and administrative expense | $2.243 million | $933,000 | $6.606 million | $4.104 million |
| Net loss | $3.922 million | $2.022 million | $11.157 million | $5.684 million |
| Net loss per share | $0.10 | $0.17 | $0.34 | $0.48 |
At September 30, 2015, cash and cash equivalents were $32.255 million, total current assets $34.151 million, current liabilities $2.242 million, total liabilities $2.550 million, and accumulated deficit $76.964 million. The company reported no remaining debt; its TBG loan was repaid during 2015. There is no meaningful product gross margin disclosed because Pieris had no product sales.
For the first nine months, operating cash use was $10.213 million, investing cash use $269,000, and financing cash inflow $24.606 million. Financing included $25.764 million net proceeds from a July public offering. Cash increased from $18.474 million at year-end 2014. The company said available cash was expected to fund operations and capital spending for at least 12 months, while also stating that additional funding would be needed to continue its plans.
Changes versus prior comparable periods
- Q3 revenue rose from $19,000 to $415,000, principally due to a $389,000 collaboration milestone. Nine-month revenue fell about 62% to $792,000, reflecting lower upfront, service and milestone revenue, partly offset by higher grant revenue.
- Q3 operating expenses increased to $4.294 million from $1.860 million; nine-month expenses rose to $11.908 million from $7.372 million. Drivers included expanded 300-Series and PRS-060 activity, PRS-080 clinical-trial and manufacturing costs, higher staffing, stock compensation and public-company costs.
- Net loss increased in both comparison periods. Lower interest expense following debt repayment partly offset higher operating expenses.
- The July offering sold 10,302,736 shares in total at $2.75 per share, generating $28.3 million gross and approximately $25.8 million net. Shares outstanding were 39,759,530 at September 30.
Outlook, risks and unusual items
- Management expected to report PRS-080 Phase I results in Q4 2015 and anticipated starting a Phase Ib/IIa study in end-stage renal disease patients in Q4 2015. It intended to select a 300-Series candidate for preclinical studies by year-end 2015; PRS-060 Phase I was targeted for 2017.
- Management expected substantial continuing losses and rising development costs, and no product-sales revenue for at least several years. Future funding needs depend on clinical progress, manufacturing, regulatory costs, partnerships and capital-market access; financing could dilute shareholders or require rights concessions.
- A TUM arbitration concerns out-license fees: Pieris calculated approximately $0.3 million due, while TUM asserted approximately $3.4 million and threatened license termination. The tribunal was preparing an award, with no decision date stated. An adverse outcome could materially affect the company. The filing reports a reserve around $302,000 in the notes but $327,937 in the legal-proceedings discussion; the precise recorded amount is unclear in the filing text.
- Management concluded disclosure controls were not effective at quarter-end because of a previously reported material weakness in finance staffing, U.S. GAAP accounting and timely reporting processes. Remediation measures were underway.
- The company was relocating its headquarters to Boston and had signed a sublease running potentially through February 2022; the occupancy start depended on completion of renovations.
- The filing reported no material changes to previously disclosed risk factors and no other material legal proceedings. Foreign-currency translation affected comprehensive loss; nine-month translation loss was $307,000.
Investor verification priorities
- Confirm the correct issuer: the supplied metadata says Pavella Therapeutics, but the filing is for Pieris Pharmaceuticals, Inc.
- Track the TUM arbitration outcome, potential payment exposure, license continuity and the difference between the reserve amounts disclosed.
- Assess cash burn, the stated 12-month runway, future financing requirements and dilution following the July offering.
- Verify delivery of the PRS-080 data and planned trial milestones, plus progress and funding demands for PRS-060 and the 300-Series.
- Monitor remediation and testing of the material weakness in internal controls.